The possible link between hIAPP accumulation and β-cell death in diabetic patients has
inspired numerous studies focusing on amyloid structures and aggregation pathways of this …

Islet amyloid deposition is a pathogenic feature of type 2 diabetes, and these deposits
contain the unique amyloidogenic peptide islet amyloid polypeptide. Autopsy studies in …

Diabetes and Alzheimer's disease are two highly prevalent diseases among the aging
population and have become major public health concerns in the 21st century, with a …

Almost a century ago, in 1901, Eugene L. Opie described “hyaline degeneration of the
islands of Langerhans” in the pancreas of patients with hyperglycemia (Figure 1). 1 A …

Islet amyloid has been recognized as a pathological entity in type 2 diabetes since the turn
of the century. It has as its unique component the islet beta-cell peptide islet amyloid …

Pancreatic amyloid is found in more than 95% of type II diabetes patients. Pancreatic
amyloid is formed by the aggregation of islet amyloid polypeptide (hIAPP or amylin), which is …

Alzheimer disease (AD) and type 2 diabetes mellitus (T2DM) are conditions that affect a
large number of people in the industrialized countries. Both conditions are on the increase …

The development of type II diabetes was shown to be associated with the formation of
amyloid fibrils consisted of the islet amyloid polypeptide (IAPP or amylin). Recently, a short …

The formation of a heterogeneous set of advanced glycation end products (AGEs) is the final
outcome of a non-enzymatic process that occurs in vivo on long-life biomolecules. This …

Islet amyloid polypeptide (IAPP, amylin) is secreted from pancreatic islet β-cells and
converted to amyloid deposits in type 2 diabetes. Conversion from soluble monomer, IAPP 1 …